Next-Gen Oral SERD Cuts Recurrence Risk in Early Breast Cancer

(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen-receptor degrader (SERD) giredestrant significantly reduced recurrence risk compared with standard…

Source link : https://www.medpagetoday.com/meetingcoverage/sabcs-vp-earlybrca/119132

Author :

Publish date : 2025-12-22 17:28:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Next-Gen Oral SERD Cuts Recurrence Risk in Early Breast Cancer

Trump Announces Lower Drug Price Deals With 9 Pharmaceutical Companies

Adding Tucatinib in First-Line Maintenance Boosts PFS in HER2-Positive Breast Cancer

Related Posts

Adding Tucatinib in First-Line Maintenance Boosts PFS in HER2-Positive Breast Cancer

Trump Announces Lower Drug Price Deals With 9 Pharmaceutical Companies

Polatuzumab-Based Combination Continues to Impress in Real-World DLBCL Analyses

Sniffing Out the Optimal Radiation Dose for Head and Neck Cancer

Fellow Nurses: Did You (or Will You) Go to Your Staff Christmas Party?

Cheddar Cheese Recalled; Nick Reiner’s Medication Change; How Safe Is U.S. Food?

Adding Tucatinib in First-Line Maintenance Boosts PFS in HER2-Positive Breast Cancer

Next-Gen Oral SERD Cuts Recurrence Risk in Early Breast Cancer

Trump Announces Lower Drug Price Deals With 9 Pharmaceutical Companies

Polatuzumab-Based Combination Continues to Impress in Real-World DLBCL Analyses

Sniffing Out the Optimal Radiation Dose for Head and Neck Cancer

Fellow Nurses: Did You (or Will You) Go to Your Staff Christmas Party?

Cheddar Cheese Recalled; Nick Reiner’s Medication Change; How Safe Is U.S. Food?

Novel Treatment Combo Ups Survival in Multiple Myeloma

Categories

Archives